Results of Operations and Financial Condition
Show detailsHide details
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
Viridian Therapeutics, Inc.\de
A biotechnology company developing new treatments for thyroid eye disease, a rare autoimmune condition that makes the tissues behind the eye swell and bulge. Its lead experimental medicine, veligrotug, is an antibody designed to block the protein driving that swelling. The company was formed under its current name in 2022, taking "Viridian" from the green pigment, a nod to fresh growth.
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 8.01 Other Events · 9.01 Financial Statements and Exhibits
5.07 Submission of Matters to a Vote of Security Holders
1.02 Termination of a Material Definitive Agreement
1.01 Entry into a Material Definitive Agreement
1.01 Entry into a Material Definitive Agreement · 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement · 8.01 Other Events · 9.01 Financial Statements and Exhibits
2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits
7.01 Regulation FD Disclosure · 9.01 Financial Statements and Exhibits